Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
10.08.2023 - - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients ...
Source: wallstreet-online.de